Staff editor
Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.
The partnership program aims to develop next-generation probiotics and therapeutics to modulate the gut microbiota to target areas like anxiety, depression and mental well-being.
It's the second agreement between Boehringer Ingelheim and BiomX focused on IBD. The first one in 2020.
Locus is developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases.
New publication reveals how a keystone strain exerts potential to impact a spectrum of health outcomes through immune and metabolic regulation.
A Transdisciplinary Doctoral Programme managed by the University of Naples Federico II through its Task Force on Microbiome Studies.
Industry
Sponsored by
SynBalance® ProBeautyShield has been selected as the ingredient of the year in beauty from within category.
The collaboration with ADM a premier global human and animal nutrition company will combine cutting-edge technologies to the pipeline of microbiome-focused innovation from Gnubiotics.
The solutions will aim to improve the diagnosis of diseases thanks to a more detailed analysis of the intestinal, oral, ocular, cancer or pulmonary microbiomes.
Patrice Cani (Université catholique de Louvain) discusses the role of Akkermansia muciniphila in the gut barrier.
